1. Fatima, Ambrin, Hoeber, Jan, Schuster, Jens, Klar, Joakim, Dahl, Niklas. 2021. Monoallelic and bi-allelic variants in NCDN cause neurodevelopmental delay, intellectual disability, and epilepsy. In American journal of human genetics, 108, 739-748. doi:10.1016/j.ajhg.2021.02.015. https://pubmed.ncbi.nlm.nih.gov/33711248/
2. Nicolas, Gaël, Sévigny, Myriam, Lecoquierre, François, Rovelet-Lecrux, Anne, Sephton, Chantelle F. 2022. A postzygotic de novo NCDN mutation identified in a sporadic FTLD patient results in neurochondrin haploinsufficiency and altered FUS granule dynamics. In Acta neuropathologica communications, 10, 20. doi:10.1186/s40478-022-01314-x. https://pubmed.ncbi.nlm.nih.gov/35151370/
3. Huang, Xiaokai, Xu, Chengwu, Dai, Haipeng, Ruan, Jichen, Wang, Juxiang. 2024. NCDN is a Potential Biomarker and Therapeutic Target for Glioblastoma. In Journal of Cancer, 15, 1067-1076. doi:10.7150/jca.90535. https://pubmed.ncbi.nlm.nih.gov/38230206/
4. Palande, Vikrant, Siegal, Tali, Detroja, Rajesh, Raviv Shay, Dorith, Frenkel-Morgenstern, Milana. 2022. Detection of gene mutations and gene-gene fusions in circulating cell-free DNA of glioblastoma patients: an avenue for clinically relevant diagnostic analysis. In Molecular oncology, 16, 2098-2114. doi:10.1002/1878-0261.13157. https://pubmed.ncbi.nlm.nih.gov/34875133/